We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Gene Therapy Targets Solid Tumors

By Biotechdaily staff writers
Posted on 03 Mar 2008
Cancer researchers have developed a novel method for treating solid tumors by infecting them with a virus engineered to carry the gene for a protein that inhibits an enzyme that is critical for tumor growth.

Previous research had shown that oncolytic herpes simplex virus (oHSV) could infect and kill human cancer cells without harming normal, healthy cells or causing disease. More...
Elaborating on this knowledge, investigators Cincinnati Children's Hospital Medical Center (OH, USA) genetically engineered oHSV to carry the gene that encodes for the protein human tissue inhibitor of metalloproteinase 3 (TIMP3).

Metalloproteinase 3, a member of the group of enzymes known as matrix metalloproteinases (MMP), collectively is capable of degrading most kinds of extracellular matrix proteins. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), and chemokine activation or inactivation. MMPs are also thought to play a major role in cellular activities such as proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis, and host defense. The MMPs are inhibited by specific endogenous tissue inhibitor of metalloproteinases (TIMPs), which comprise a family of four protease inhibitors: TIMP1, TIMP2, TIMP3 and TIMP4.

Results published in the February 15, 2008, issue of the journal Cancer Research revealed that treatment with the engineered virus (called rQT3) reduced new blood vessel development and increased toxicity to neuroblastoma and peripheral nerve sheath tumor-cells. In addition, rQT3 treatment resulted in longer life spans in mice carrying these tumors as compared to mouse models receiving just saline or other treatments.

"Malignant solid tumors are still very difficult to treat effectively, especially without causing harm to normal tissues, so we need to find innovative therapeutic approaches,” explained senior author Dr. Timothy Cripe, a physician and researcher at Cincinnati Children's Hospital Medical Center. "In our study, this tumor-targeting viral therapy enhanced anti-tumor activity by stimulating multiple biological processes, including directly killing the cancer cells and reducing the formation of blood vessels that fed the tumors. These data support continuing development and study of our tumor-targeted viral therapy to fight cancer.”


Related Links:
Cincinnati Children's Hospital Medical Center

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.